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The aim of our recent study ‘The reliability of immunoassays to detect autoantibodies in 
patients with myositis is dependent on autoantibody specificity’ was to determine the 
reliability of commercially available immunoassays to detect myositis specific autoantibodies 
(MSA) [1]. In order to investigate this a variety of statistical methods were used to assist with 
data interpretation. Sensitivity and specificity were calculated for each autoantibody and are 
shown in tables 1 and 2 [1]. As stated by Dr Sabour in the associated matters arising letter [2], 
these provide useful measures of the accuracy of the test. Positive and negative predictive 
values would not be helpful here, as these depend on the prevalence of MSA in the 
background population which would be expected to vary depending on which patient groups 
are subject to testing. 
 
Cohens K was chosen as a measure of agreement between the commercial immunoassay 
being evaluated and immunoprecipitation as the gold standard test. This has been used 
previously in similar studies evaluating MSA testing [3-5].  Results provided by 
immunoprecipitation are not quantitative but simply positive or negative. Similarly, whilst the 
DTek blue diver assay provides a quantitative and the Euroimmun line blot semi-quantitative 
results there is, as yet, no known robust clinical application for MSA titres. All results were 
therefore categorised as positive or negative using manufacturers recommended cut-offs. 
Intra class correlation coefficient or Bland Altman plots suggested by Dr Sabour could not be 
usefully applied to this type of data. Cohens K takes into account the possibility of agreement 
occurring by chance and is therefore thought to be a more robust measure than simple 
percentage agreement calculations. We are aware that a potential limitation includes that 
different K values could be obtained for the same percentage agreement if one test were to 
give similar percentages in each category (i.e. an equal number of positives and negatives). 
This should not and did not occur in this study as samples were selected on the basis of their 
MSA status as determined by immunoprecipitation. For each MSA of interest there were 10-
25 known positives and 362-460 known negatives, as shown in the results tables for each 
assay. For neither commercial assay evaluated was there anywhere approaching an equal 
number of positive and negative results for any of the MSA assessed. 
 
We concluded that the assays analysed do not perform well for all MSA specificities and 
overall false positives are relatively common. Whilst this may seem a sweeping statement, 
our results revealed that Euroimmun line blot failed to detect any of the 14 anti-OJ samples 
and the DTek blue diver detected just one of these and none of the nine anti-Zo samples. Our 
conclusion was that this is an exceptionally poor performance for these MSA and this is an 
important message to clinicians. Furthermore, while the false positive rate amongst healthy 
controls of approximately 13% for both assays was lower than that reported by some 
studies[6] we would argue that this is high enough to have significant implications for 
widespread clinical testing and our conclusions are therefore valid. 
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